Regeneron Pharmaceuticals (REGN) shares soared to a fresh two-year high on Oct. 30 after blockbuster inflammation drug Dupixent powered a substantial Q3 earnings beat. Developed in collaboration with Sanofi (SNY), the treatment brought in roughly $6.5 billion in quarterly sales, handily beating the $6.1 billion consensus estimate.
Versus its year-to-date low, Regeneron stock is now trading roughly 50% higher.